HN2- SYNTHESIS, CHARACTERIZATION, AND BIOLOGICAL EVALUATION OF IBUPROFEN DERIVATIVE AGAINST COLON AND BREAST CANCER CELL-LINES

Awatif Abed Ibrahim Alani
Iraq

Awatif Abed Ibrahim Alani

Inventor in Beirut International Innovation Show BIIS 2021

Zaid Mahdi Jaber AlObaidi
Iraq

Zaid Mahdi Jaber AlObaidi

Inventor in Beirut International Innovation Show BIIS 2021

Overview

The synthesis of novel conjugate of ibuprofen with the 6-
methyl-Nl-(4-(pyridin-3-yl) pyrimidin-2-yl) benzene-1,3-diamine derivative
showed a potential antiproliferative activity against both colon cancer
and breast cancer cell lines. The chemical structure was characterized
and confirmed by spectral (FTIR,IH-NMR and l3C NMR), and the Differential
Scanning Colorimetry (DSC) Thermal analyzer. While the biological
activity was estimated by Genetic Optimization of Ligand Docking
(GOLD) software supplied by Cambridge Crystallographic Data Centre
(CCDC) and conducted in vitro with the MTT and the calculation of
the IC50. The docking process was successfully performed and the chemical
synthesis yield was reasonably high. The spectral interpretations show
characteristic identification of the target chemical compound. The results
indicated a powerful antitumor drug against breast cancer (MCF7) and
colon (HCTll6) cell lines. On the other hand, to evaluate the toxicity profile,
the Madin-Darby Canine Kidney (MDCK) normal (noncancerous) cell
line, was utilized.